Source - SMW
Circassia Pharmaceuticals plc announced Thursday that it received a multi-year contract for its Niox Vero asthma management products from Vizient.

The contract is expected to provide Circassia with a simplified route to access Vizient members as potential new customers, helping it expand its number of accounts while offering savings opportunities for niox users.
 
Steve Harris, Circassia's CEO, said: 'Circassia is proud to be awarded this prestigious Vizient Innovative Technology contract, which recognises the important role Niox Vero plays in assisting asthma diagnosis and management.'

'Vizient is the largest member-driven healthcare improvement company in the United States, and its diverse membership and customer base includes academic medical centres, paediatric facilities, community hospitals, integrated health delivery networks and non-acute health care providers with combined purchasing volume of approximately $100 billion annually.' 


At 8:41am: (LON:CIR) Circassia Pharmaceuticals Plc share price was +0.8p at 94.5p